

Ocular Inflammation and Pain - Pipeline Insight, 2021

https://marketpublishers.com/r/OCABD51FA383EN.html

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: OCABD51FA383EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Ocular Inflammation and Pain – Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Inflammation and Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ocular Inflammation and Pain Understanding

Ocular Inflammation and Pain: Overview

Inflammation is body's response to injury, infection or irritation. In some cases, inflammation can occur in response to normally harmless substances, such as dust, grass or pollen. This is an allergic reaction. The immune system may also trigger inflammation in response to the body's own tissues. This is called an autoimmune reaction. Eye inflammation occurs in response to infection, allergies, autoimmune disorders, irritation, or injury or trauma to the eye or eyelid. Symptoms of eye inflammation can affect the eyes, eyelids, or surrounding tissues and include: Blurry vision, Pain, Redness, Swelling, Tearing, Unusual warmth or heat. Ocular inflammation is also often present in patients with systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, Wegener's



granulomatosis, Sj?gren's syndrome, polyarteritis nodosa, primary antiphospholipid syndrome, Beh?et's syndrome, Kawasaki disease, Cogan's syndrome, and relapsing polychondritis.

'Ocular Inflammation and Pain - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Inflammation and Pain pipeline landscape is provided which includes the disease overview and Ocular Inflammation and Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Inflammation and Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Inflammation and Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Inflammation and Pain R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Inflammation and Pain.

Ocular Inflammation and Pain Emerging Drugs Chapters

This segment of the Ocular Inflammation and Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Inflammation and Pain Emerging Drugs

APP13007: Formosa pharmaceuticals

APP13007, derived from our proprietary APNT formulation platform, is an aqueousbased ophthalmic nanosuspension positioned for the treatment of post-operative pain



and inflammatory eye conditions. The active ingredient in APP13007 is a potent corticosteroid agent whose efficacy and safety for dermatological use has been well established for more than 30 years in the US, Europe, and Japan. APP13007 will represent the first ophthalmic application of the known API. APP13007 completed Phase II studies in 2020 and has just started Phase III studies in the United States in March, 2021.

Further product details are provided in the report......

Ocular Inflammation and Pain: Therapeutic Assessment

This segment of the report provides insights about the different Ocular Inflammation and Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Inflammation and Pain

There are approx. 5+ key companies which are developing the therapies for Ocular Inflammation and Pain. The companies which have their Ocular Inflammation and Pain drug candidates in the most advanced stage, i.e. Phase III include, Formosa pharmaceuticals.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of


Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates



Route of Administration

Ocular Inflammation and Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as



Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Inflammation and Pain: Pipeline Development Activities



The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Inflammation and Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Inflammation and Pain drugs.

Ocular Inflammation and Pain Report Insights

Ocular Inflammation and Pain Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ocular Inflammation and Pain Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:



How many companies are developing Ocular Inflammation and Pain drugs?

How many Ocular Inflammation and Pain drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Inflammation and Pain?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Inflammation and Pain therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ocular Inflammation and Pain and their status?

What are the key designations that have been granted to the emerging drugs?



Contents

Introduction

Executive Summary

Ocular Inflammation and Pain: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

APP13007: Formosa pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

RX-10045: A.T. Resolve SARL

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early stage products (Phase I/II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities



Drug profiles in the detailed report Inactive Products

Comparative Analysis

Ocular Inflammation and Pain Key Companies

Ocular Inflammation and Pain Key Products

Ocular Inflammation and Pain- Unmet Needs

Ocular Inflammation and Pain- Market Drivers and Barriers

Ocular Inflammation and Pain-Future Perspectives and Conclusion

Ocular Inflammation and Pain Analyst Views

Ocular Inflammation and Pain Key Companies

Appendix



List Of Tables

LIST OF TABLES

Table 1 Total Products for Ocular Inflammation and Pain

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products



List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Ocular Inflammation and Pair
--

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products



I would like to order

Product name: Ocular Inflammation and Pain - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/OCABD51FA383EN.html

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/OCABD51FA383EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970